Sam is an associate in our Life Sciences and Chemistry group and his practice focuses on RNA therapeutics, gene editing and delivery modalities, antibodies and synthetic biology. He has a strong practice in contentious matters before the EPO, having handled oppositions and appeals relating to everything from approved drugs to game changing gene editing platforms.
Sam has experience in conducting infringement risk exercises, advising on licensing deals, and coordinating prosecution of large global patent families. His focus is always on providing the best commercial outcomes for his clients, be that clearing the way with attacking oppositions, defending key assets or building strong portfolios to support licensing deals and fundraising.
Sam has also broadened his practice whilst on multiple secondments. He spent time gaining valuable in-house experience on secondment supporting a start-up in the RNA delivery space. On a separate secondment, Sam also supported multi-national litigation relating to mRNA vaccines.
Sam graduated with a BSc. (Hons) in biochemistry from the University of Manchester in 2014. Following his undergraduate degree Sam completed a PhD in structural biology at the Manchester Institute for Biotechnology. His research focused on understanding the structure-function relationship of novel enzymes with potential uses in the production of biofuels and bioplastics.